The National Health Care Institute carried out an assessment of whether, based on the criteria of the Medicines Reimbursement System (GVS), the medicine migalastat (Galafold®) is interchangeable with any other product that is included in the GVS.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.